Cognitive disorder and Cerebral atrophy
Summary:
Cerebral atrophy is found among people with Cognitive disorder, especially for people who are female, 40-49 old.
The study analyzes which people have Cerebral atrophy with Cognitive disorder. It is created by eHealthMe based on reports of 14 people who have Cognitive disorder from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.
What is Cognitive disorder?
Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving) is found to be associated with 1,657 drugs and 1,727 conditions by eHealthMe. Check the latest studies of Cognitive disorder.
What is Cerebral atrophy?
Cerebral atrophy (decrement in size of brain) is found to be associated with 807 drugs and 856 conditions by eHealthMe. Check the latest studies of Cerebral atrophy.
14 people who have Cognitive Disorder and Cerebral Atrophy are studied.

Gender of people who have Cognitive Disorder and experienced Cerebral Atrophy *:
- female: 92.86 %
- male: 7.14 %
Age of people who have Cognitive Disorder and experienced Cerebral Atrophy *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 64.29 %
- 50-59: 7.14 %
- 60+: 28.57 %
Common co-existing conditions for these people *:
- Breast Cancer Female: 7 people, 50.00%
- Breast Cancer: 7 people, 50.00%
- Depression: 5 people, 35.71%
- Merycism (a rare disease in which food is chewed, swallowed, and then returned to the mouth and chewed again): 4 people, 28.57%
- Agitation (state of anxiety or nervous excitement): 4 people, 28.57%
- Parkinson's Disease: 2 people, 14.29%
- Dyskinesia (abnormality or impairment of voluntary movement): 2 people, 14.29%
- Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 1 person, 7.14%
- Prostatic Disorder: 1 person, 7.14%
- Disturbance In Attention: 1 person, 7.14%
Common drugs taken by these people *:
- Xenazine: 2 people, 14.29%
- Exelon: 2 people, 14.29%
- Ditropan: 2 people, 14.29%
- Cymbalta: 2 people, 14.29%
- Azilect: 2 people, 14.29%
- Fenofibrate: 1 person, 7.14%
- Donepezil: 1 person, 7.14%
- Dalfampridine: 1 person, 7.14%
Common symptoms for these people *:
- Merycism (a rare disease in which food is chewed, swallowed, and then returned to the mouth and chewed again): 9 people, 64.29%
- Logorrhea: 9 people, 64.29%
- Suicidal Ideation: 9 people, 64.29%
- Disturbance In Attention: 9 people, 64.29%
- Agitation (state of anxiety or nervous excitement): 9 people, 64.29%
- Mood Swings (an extreme or rapid change in mood): 9 people, 64.29%
- Depressed Mood: 9 people, 64.29%
- Memory Loss: 9 people, 64.29%
- Arachnoid Cyst: 7 people, 50.00%
- Iatrogenic Injury (iatrogenic injury is a form of medical error): 2 people, 14.29%
* Approximation only. Some reports may have incomplete information.
Do you take medications and have Cerebral atrophy?
- Check whether Cerebral atrophy is associated with a drug or a conditionRelated studies:
Treatments, associated drugs and conditions:
- Cognitive disorder (56,151 reports)
- Cerebral atrophy (6,052 reports)
All the drugs that are associated with Cerebral atrophy:
- Cerebral atrophy (807 drugs)
All the conditions that are associated with Cerebral atrophy:
- Cerebral atrophy (856 conditions)
How the study uses the data?
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
The study is based on Cerebral atrophy and Cognitive disorder, and their synonyms.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Flexeril and Ibrance - 12 seconds ago
- Could Uvadex cause Anaemia? - 19 seconds ago
- Could Prochlorperazine Maleate cause Libido Decreased? - 19 seconds ago
- Could Mycophenolate Mofetil cause Hepatitis C Rna Increased? - 26 seconds ago
- Drug interactions of Oxycontin and L-Cysteine - 32 seconds ago
- Could Mvasi cause Urinary Tract Infection? - 34 seconds ago
- Drug interactions of Loratadine and Fenofibrate - 43 seconds ago
- Could Cordarone cause Listless? - 51 seconds ago
- Drug interactions of Letrozole and Soma - 54 seconds ago
- Zenatane vs. Ampicillin Trihydrate, side effect and effectiveness comparison - a minute ago